@article{schneider_comparison_2017,
	title = {Comparison of remicade to curcumin for the treatment of {Crohn}’s disease: {A} systematic review},
	volume = {33},
	issn = {0965-2299},
	shorttitle = {Comparison of remicade to curcumin for the treatment of {Crohn}’s disease},
	url = {http://www.sciencedirect.com/science/article/pii/S0965229917300870},
	doi = {10.1016/j.ctim.2017.06.002},
	abstract = {Objective
The aim of this study was to review the literature to assess if there is evidence to support the use of Curcumin as a safe complementary therapy in treating Crohn’s Disease (CD) in conjunction with Remicade.
Design
Systematic searches were performed by three researchers using electronic databases (ProQuest Medical Library, CINAHL Complete, and PUBMED) to locate and identify articles to meet a predetermined set of inclusion criteria. Specifically full text, peer-reviewed articles published after 2007 were included if they studied human participants 18 years or older.
Results
Tumor necrosis factor-alpha (TNF-a) and Interleukin-1 (IL-1) levels increase in CD patients. Remicade reduces TNF-a in adults with CD. The issues are eventual loss of response (LOR) once IL-1 increases, and severe risks such as malignancy. CD patients using Curcumin saw a 55 point mean reduction in the Crohn’s Disease Activity Index, reducing IL-1 and Crp. Plus it reduced TNF-a and PPMTase which improved colorectal cancer outcomes.
Conclusions
LOR of Remicade occurs when IL-1 increases, and it can cause malignancy. Research shows Curcumin reduces IL-1 and improves cancer outcomes. Future research, using both Remicade and Curcumin, would have to be done, but preliminary data would suggest using both would reduce LOR. Curcumin, even by itself, was found to be a cheap and safe way to reduce CD symptoms and inflammatory markers.},
	language = {en},
	urldate = {2020-10-12},
	journal = {Complementary Therapies in Medicine},
	author = {Schneider, Allaire and Hossain, Ivy and VanderMolen, Julia and Nicol, Kara},
	month = aug,
	year = {2017},
	keywords = {C reactive protein, Cancer, Crohn’s, Curcumin, Inflammation, Remicade, TNF},
	pages = {32--38},
}

{"_id":"S92A6yvpFjXAzit9E","bibbaseid":"schneider-hossain-vandermolen-nicol-comparisonofremicadetocurcuminforthetreatmentofcrohnsdiseaseasystematicreview-2017","author_short":["Schneider, A.","Hossain, I.","VanderMolen, J.","Nicol, K."],"bibdata":{"bibtype":"article","type":"article","title":"Comparison of remicade to curcumin for the treatment of Crohn’s disease: A systematic review","volume":"33","issn":"0965-2299","shorttitle":"Comparison of remicade to curcumin for the treatment of Crohn’s disease","url":"http://www.sciencedirect.com/science/article/pii/S0965229917300870","doi":"10.1016/j.ctim.2017.06.002","abstract":"Objective The aim of this study was to review the literature to assess if there is evidence to support the use of Curcumin as a safe complementary therapy in treating Crohn’s Disease (CD) in conjunction with Remicade. Design Systematic searches were performed by three researchers using electronic databases (ProQuest Medical Library, CINAHL Complete, and PUBMED) to locate and identify articles to meet a predetermined set of inclusion criteria. Specifically full text, peer-reviewed articles published after 2007 were included if they studied human participants 18 years or older. Results Tumor necrosis factor-alpha (TNF-a) and Interleukin-1 (IL-1) levels increase in CD patients. Remicade reduces TNF-a in adults with CD. The issues are eventual loss of response (LOR) once IL-1 increases, and severe risks such as malignancy. CD patients using Curcumin saw a 55 point mean reduction in the Crohn’s Disease Activity Index, reducing IL-1 and Crp. Plus it reduced TNF-a and PPMTase which improved colorectal cancer outcomes. Conclusions LOR of Remicade occurs when IL-1 increases, and it can cause malignancy. Research shows Curcumin reduces IL-1 and improves cancer outcomes. Future research, using both Remicade and Curcumin, would have to be done, but preliminary data would suggest using both would reduce LOR. Curcumin, even by itself, was found to be a cheap and safe way to reduce CD symptoms and inflammatory markers.","language":"en","urldate":"2020-10-12","journal":"Complementary Therapies in Medicine","author":[{"propositions":[],"lastnames":["Schneider"],"firstnames":["Allaire"],"suffixes":[]},{"propositions":[],"lastnames":["Hossain"],"firstnames":["Ivy"],"suffixes":[]},{"propositions":[],"lastnames":["VanderMolen"],"firstnames":["Julia"],"suffixes":[]},{"propositions":[],"lastnames":["Nicol"],"firstnames":["Kara"],"suffixes":[]}],"month":"August","year":"2017","keywords":"C reactive protein, Cancer, Crohn’s, Curcumin, Inflammation, Remicade, TNF","pages":"32–38","bibtex":"@article{schneider_comparison_2017,\n\ttitle = {Comparison of remicade to curcumin for the treatment of {Crohn}’s disease: {A} systematic review},\n\tvolume = {33},\n\tissn = {0965-2299},\n\tshorttitle = {Comparison of remicade to curcumin for the treatment of {Crohn}’s disease},\n\turl = {http://www.sciencedirect.com/science/article/pii/S0965229917300870},\n\tdoi = {10.1016/j.ctim.2017.06.002},\n\tabstract = {Objective\nThe aim of this study was to review the literature to assess if there is evidence to support the use of Curcumin as a safe complementary therapy in treating Crohn’s Disease (CD) in conjunction with Remicade.\nDesign\nSystematic searches were performed by three researchers using electronic databases (ProQuest Medical Library, CINAHL Complete, and PUBMED) to locate and identify articles to meet a predetermined set of inclusion criteria. Specifically full text, peer-reviewed articles published after 2007 were included if they studied human participants 18 years or older.\nResults\nTumor necrosis factor-alpha (TNF-a) and Interleukin-1 (IL-1) levels increase in CD patients. Remicade reduces TNF-a in adults with CD. The issues are eventual loss of response (LOR) once IL-1 increases, and severe risks such as malignancy. CD patients using Curcumin saw a 55 point mean reduction in the Crohn’s Disease Activity Index, reducing IL-1 and Crp. Plus it reduced TNF-a and PPMTase which improved colorectal cancer outcomes.\nConclusions\nLOR of Remicade occurs when IL-1 increases, and it can cause malignancy. Research shows Curcumin reduces IL-1 and improves cancer outcomes. Future research, using both Remicade and Curcumin, would have to be done, but preliminary data would suggest using both would reduce LOR. Curcumin, even by itself, was found to be a cheap and safe way to reduce CD symptoms and inflammatory markers.},\n\tlanguage = {en},\n\turldate = {2020-10-12},\n\tjournal = {Complementary Therapies in Medicine},\n\tauthor = {Schneider, Allaire and Hossain, Ivy and VanderMolen, Julia and Nicol, Kara},\n\tmonth = aug,\n\tyear = {2017},\n\tkeywords = {C reactive protein, Cancer, Crohn’s, Curcumin, Inflammation, Remicade, TNF},\n\tpages = {32--38},\n}\n\n","author_short":["Schneider, A.","Hossain, I.","VanderMolen, J.","Nicol, K."],"key":"schneider_comparison_2017","id":"schneider_comparison_2017","bibbaseid":"schneider-hossain-vandermolen-nicol-comparisonofremicadetocurcuminforthetreatmentofcrohnsdiseaseasystematicreview-2017","role":"author","urls":{"Paper":"http://www.sciencedirect.com/science/article/pii/S0965229917300870"},"keyword":["C reactive protein","Cancer","Crohn’s","Curcumin","Inflammation","Remicade","TNF"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/ckelleyt","dataSources":["W5PhLT7vuF6ko8d7J","tTydwtpFKyvDpy8qn"],"keywords":["c reactive protein","cancer","crohn’s","curcumin","inflammation","remicade","tnf"],"search_terms":["comparison","remicade","curcumin","treatment","crohn","disease","systematic","review","schneider","hossain","vandermolen","nicol"],"title":"Comparison of remicade to curcumin for the treatment of Crohn’s disease: A systematic review","year":2017}